Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 1/20 | 0.40 |
| ▸ | ADAM17 | P78536 | 3/20 | 0.39 |
| ▸ | GHSR | Q92847 | 2/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | CCKAR | P32238 | 3/20 | 0.37 |
| ▸ | CCKBR | P32239 | 3/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
| ▸ | KDM1A | O60341 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
| ▸ | HSD17B13 | Q7Z5P4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4827419 | 0.86 | ADAM17 (0.44) | CHRNA7ADAM17GHSRCCKARCCKBR | |
| SCHEMBL4825614 | 0.84 | HPGD (0.46) | CHRNA7ADAM17GHSR | |
| SCHEMBL4819428 | 0.83 | ADAM17 (0.44) | CHRNA7ADAM17GHSRKCNH2CCKAR | |
| SCHEMBL4826756 | 0.79 | CHRNA7 (0.47) | CHRNA7GHSRKCNH2CCKARCCKBR | |
| SCHEMBL8251025 | 0.79 | CNR2 (0.50) | CHRNA7GHSRKCNH2CNR2HDAC1 | |
| SCHEMBL4822006 | 0.79 | CHRNA7 (0.47) | CHRNA7GHSRKCNH2CCKARCCKBR | |
| SCHEMBL4823902 | 0.79 | CHRNA7 (0.47) | CHRNA7GHSRKCNH2CCKARCCKBR | |
| SCHEMBL5259022 | 0.79 | CHRNA7 (0.46) | CHRNA7GHSRKCNH2CNR2HDAC1 | |
| SCHEMBL4825563 | 0.79 | CHRNA7 (0.46) | CHRNA7GHSRKCNH2CCKARCCKBR | |
| SCHEMBL14193441 | 0.78 | CHRNA7 (0.51) | CHRNA7GHSRKCNH2CCKARCCKBR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7358373-B2 | Cathepsin K inhibitors | ROCHE PALO ALTO LLC (US) | 2008-04-15 | — | — | US | disclosed |
| US-7358373-B2 | Cathepsin K inhibitors | ROCHE PALO ALTO LLC (US) | 2008-04-15 | — | — | US | disclosed |
| US-7358373-B2 | Cathepsin K inhibitors | ROCHE PALO ALTO LLC (US) | 2008-04-15 | — | — | US | disclosed |
| US-20070032484-A1 | Cathepsin K inhibitors | ROCHE PALO ALTO LLC | 2007-02-08 | — | — | US | disclosed |
| US-20070032484-A1 | Cathepsin K inhibitors | ROCHE PALO ALTO LLC | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032484-A1 | Cathepsin K inhibitors | CTSK, CTSS, CTSF | CHRNA7 3660/4885ADAM17 171/4885GHSR 686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.